drugset / Trial / NCT07808697
A Study to Evaluate the Safety, Reactogenicity, and Immunogenicity of mRNA-1283 in Participants ≥6 Months to <12 Years of Age
RandomizedParallel-groupQuadruple-blindPrevention
Summary
This study will evaluate 2 dose levels of mRNA-1283 in participants ≥6 months to \<12 years to determine the optimal dose level per age group.
Timeline
- Start
- 2026-09-01
- Primary completion
- 2029-08-30
- Completion
- 2029-08-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | mRNA-1273 | Messenger RNA (mRNA) | — | Intramuscular |
| Subject | mRNA-1283 | Messenger RNA (mRNA) | — | Intramuscular |